On November 1, 2023, Dr. Elliott Sigal, a member of the Board of Directors of Adaptimmune Therapeutics plc resigned from the company?s Board of Directors effective on November 1, 2023. Dr. Sigal?s intention to resign from the Board when Dr. Kristen Hege?s appointment to the Board became effective on November 1, 2023 was previously announced by the Company on March 6, 2023 in connection with the strategic combination between Adaptimmune and TCR ² Therapeutics Inc. Dr. Sigal?s decision to resign was not as a result of any disagreement with the Company or its management but was in order to more fully pursue other commitments.